Skip to main content

Table 3 Effect of simvastatin allocation on site-specific cancer incidence

From: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]

Cancer site Simvastatin-allocated (10,269) Placebo-allocated (10,267) Event rate ratio (& 95% CI) P-value
Respiratory     
   Lung/larynx 171 (1.7%) 157 (1.5%) 1.08 (0.87 – 1.34)  
   Other 8 (0.1%) 10 (0.1%) 0.79 (0.32 – 2.00)  
   Subtotal: Respiratory 179 (1.7%) 167 (1.6%) 1.06 (0.86 – 1.31) 0.6
Gastrointestinal     
   Upper GI 74 (0.7%) 62 (0.6%) 1.18 (0.84 – 1.65)  
   Colon/rectum 114 (1.1%) 131 (1.3%) 0.86 (0.67 – 1.11)  
   Other 41 (0.4%) 33 (0.3%) 1.23 (0.78 – 1.94)  
   Subtotal: Gastrointestinal 228 (2.2%) 223 (2.2%) 1.01 (0.84 – 1.22) 0.9
Connective tissue     
   Female breast 38 (1.5%) 51 (2.0%) 0.74 (0.49 – 1.12)  
   Melanoma 17 (0.2%) 10 (0.1%) 1.66 (0.78 – 3.54)  
   Other 5 (0.0%) 7 (0.1%) 0.71 (0.23 – 2.20)  
   Subtotal: Connective tissue 60 (0.6%) 68 (0.7%) 0.87 (0.62 – 1.24) 0.4
Genitourinary     
   Renal 23 (0.2%) 22 (0.2%) 1.04 (0.58 – 1.86)  
   Bladder 74 (0.7%) 90 (0.9%) 0.81 (0.60 – 1.11)  
   Prostate 145 (1.9%) 145 (1.9%) 0.99 (0.79 – 1.25)  
   Gynaecological 19 (0.7%) 18 (0.7%) 1.05 (0.55 – 2.00)  
   Other 6 (0.1%) 6 (0.1%) 0.99 (0.32 – 3.08)  
   Subtotal: Genitourinary 259 (2.5%) 272 (2.6%) 0.94 (0.80 – 1.12) 0.5
Haematological     
   Leukaemia/lymphoma 42 (0.4%) 32 (0.3%) 1.30 (0.82 – 2.05)  
   Other 23 (0.2%) 23 (0.2%) 0.99 (0.55 – 1.76)  
   Subtotal: Haematological 64 (0.6%) 52 (0.5%) 1.22 (0.85 – 1.75) 0.3
Other & unspecified 54 (0.5%) 57 (0.6%) 0.94 (0.65 – 1.36) 0.7
ALL CANCERS* 814 (7.9%) 803 (7.8%) 1.00 (0.91 – 1.11) 0.9
  1. * Prespecified that analyses of cancer incidence were to exclude non-melanoma skin cancer (243 [2.4%] simvastatin-allocated versus 202 [2.0%] placebo-allocated; p = 0.06).